Antivirals Targeting the Neuraminidase

Gubareva, Larisa V.; Mohan, Teena

doi:10.1101/cshperspect.a038455

Cited by 36 publications

(29 citation statements)

References 201 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since NA is responsible for viral entry and releasing viral particles into cells, inhibition of the NA enzyme has been a primary treatment of influenza [e.g., including oseltamivir (Tamiflu)] (47,48). Antibodies that bind to NA were suggested to provide durable and broad protection against divergent influenza strains (49-52).…”

Section: Discussionmentioning

confidence: 99%

A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity

et al. 2020

View full text Add to dashboard Cite

Sato-Kaneko et al.Protective Liposomal TLR4/7 Vaccine titers and cytokine levels. The combination adjuvant induced a greater diversity in B cell clonotypes of immunoglobulin heavy chain (IGH) genes in the draining lymph nodes and antibodies against a broad spectrum of HA epitopes encompassing HA head and stalk domains and with cross-reactivity against different subtypes of HA and NA. This novel combination liposomal adjuvant contributes to a more broadly protective vaccine while demonstrating an attractive safety profile.

show abstract

Section: Discussionmentioning

confidence: 99%

A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Due to the emergence of drug resistance, it remains an urgent need to develop anti-influenza agents. Novel antivirals such as A-192558 and A-315675 are still under development ( Gubareva and Mohan, 2020 ).…”

Section: Human Influenza Virusmentioning

confidence: 99%

Antiviral Classification

Jing

Pan

et al. 2021

Encyclopedia of Virology

View full text Add to dashboard Cite

Over the past 60 years, more than 100 antiviral drugs or their combinations have been approved for clinical use. Antiviral drugs can be classified according to their chemical nature (e.g., small-molecules, peptides, biologics) or mechanisms of drug actions against specific viral proteins (e.g., polymerase inhibitors, protease inhibitors, glycoprotein inhibitors). This article provides an overview of antiviral classifications in 10 important human viruses: hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), human cytomegalovirus (HCMV), herpes simplex virus (HSV), variola virus (human smallpox), varicella zoster virus (VZV), influenza virus, respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

show abstract

“…NA constitutes a glycoprotein located in the envelope of influenza viruses that help mature virus particles separate from infected host cells [ 40 ]. Notably, influenza can be effectively treated by inhibiting the activity of NA.…”

Section: Development Of Universal Vaccines Targeting Influenza Virmentioning

confidence: 99%

Progress in the Development of Universal Influenza Vaccines

Sun

Luo

Chen

et al. 2020

Viruses

View full text Add to dashboard Cite

Influenza viruses pose a significant threat to human health. They are responsible for a large number of deaths annually and have a serious impact on the global economy. There are numerous influenza virus subtypes, antigenic variations occur continuously, and epidemic trends are difficult to predict—all of which lead to poor outcomes of routine vaccination against targeted strain subtypes. Therefore, the development of universal influenza vaccines still constitutes the ideal strategy for controlling influenza. This article reviews the progress in development of universal vaccines directed against the conserved regions of hemagglutinin (HA), neuraminidase (NA), and other structural proteins of influenza viruses using new technologies and strategies with the goals of enhancing our understanding of universal influenza vaccines and providing a reference for research into the exploitation of natural immunity against influenza viruses.

show abstract

Antivirals Targeting the Neuraminidase

Cited by 36 publications

References 201 publications

A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity

A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity

Antiviral Classification

Progress in the Development of Universal Influenza Vaccines

Contact Info

Product

Resources

About